PMID- 29373811
OWN - NLM
STAT- MEDLINE
DCOM- 20200214
LR  - 20220317
IS  - 1096-0384 (Electronic)
IS  - 0003-9861 (Linking)
VI  - 665
DP  - 2019 Apr 15
TI  - Long non-coding RNA CASC2 regulates Sprouty2 via functioning as a competing 
      endogenous RNA for miR-183 to modulate the sensitivity of prostate cancer cells 
      to docetaxel.
PG  - 69-78
LID - S0003-9861(17)30840-8 [pii]
LID - 10.1016/j.abb.2018.01.013 [doi]
AB  - Prostate cancer (PC) is the most common cancer in men; however, limited effect is 
      obtained due to the therapy resistance. CASC2 acts as a tumor suppressor in human 
      malignancies serving as a ceRNA for miRNAs; Sprouty2 (SPRY2), a key antagonist of 
      RTK signaling, also serves as a tumor suppressor. Herein, CASC2 and SPRY2 
      expression was down-regulated in PC tissues and cell lines; the overexpression of 
      CASC2 and SPRY2 could suppress PC cell proliferation, promote PC cell apoptosis, 
      and enhance the sensitivity of PC cells to docetaxel. CASC2 positively regulated 
      SPRY2 expression and inhibited downstream extracellular regulated protein kinases 
      (ERK) signaling activation through SPRY2. By using online tools, miR-183 might be 
      a direct target of CASC2, and might simultaneously bind to the 3'UTR of SPRY2. 
      The direct binding between CASC2, miR-183 and SPRY2 was then validated; miR-183 
      inhibition enhanced the cytotoxicity of docetaxel on PC cells, which could be 
      partially attenuated by SPRY2 knockdown. In summary, CASC2 competes with SPRY2 
      for miR-183 binding to rescue the expression of SPRY2 in PC cells, thus enhancing 
      the sensitivity of PC cells to docetaxel through SPRY2 downstream ERK signaling 
      pathway; CASC2 and SPRY2 might be novel adjuvants for docetaxel-based 
      chemotherapy for PC.
CI  - Copyright (c) 2018. Published by Elsevier Inc.
FAU - Gao, Weiyin
AU  - Gao W
AD  - Department of Urology Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi 330006, PR China.
FAU - Lin, Shuangquan
AU  - Lin S
AD  - Department of Urology Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi 330006, PR China.
FAU - Cheng, Cheng
AU  - Cheng C
AD  - Department of Urology Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi 330006, PR China.
FAU - Zhu, Anyi
AU  - Zhu A
AD  - Department of Urology Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi 330006, PR China.
FAU - Hu, Yingbo
AU  - Hu Y
AD  - Department of Urology Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi 330006, PR China.
FAU - Shi, Zimin
AU  - Shi Z
AD  - Department of Urology Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi 330006, PR China.
FAU - Zhang, Xiao
AU  - Zhang X
AD  - Department of Urology Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi 330006, PR China.
FAU - Hong, Zhengdong
AU  - Hong Z
AD  - Department of Urology Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi 330006, PR China. Electronic address: 
      gwymamanet@126.com.
LA  - eng
PT  - Journal Article
DEP - 20180131
PL  - United States
TA  - Arch Biochem Biophys
JT  - Archives of biochemistry and biophysics
JID - 0372430
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (MIRN183 microRNA, human)
RN  - 0 (Membrane Proteins)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (SPRY2 protein, human)
RN  - 0 (Tumor Suppressor Proteins)
RN  - 0 (long non-coding RNA CASC2, human)
RN  - 15H5577CQD (Docetaxel)
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Cell Line, Tumor
MH  - Docetaxel/*pharmacology
MH  - Drug Resistance, Neoplasm/genetics
MH  - Gene Knockdown Techniques
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins/*genetics
MH  - Male
MH  - Membrane Proteins/*genetics
MH  - MicroRNAs/*genetics
MH  - Prostatic Neoplasms/genetics/*pathology
MH  - RNA/*genetics
MH  - RNA, Long Noncoding/*genetics
MH  - Tumor Suppressor Proteins/*genetics
OTO - NOTNLM
OT  - CASC2
OT  - Chemoresistance
OT  - ERK signaling
OT  - Prostate cancer (PC)
OT  - Sprouty2 (SPRY2)
OT  - miR-183
EDAT- 2018/01/27 06:00
MHDA- 2020/02/15 06:00
CRDT- 2018/01/27 06:00
PHST- 2017/12/11 00:00 [received]
PHST- 2018/01/13 00:00 [revised]
PHST- 2018/01/21 00:00 [accepted]
PHST- 2018/01/27 06:00 [pubmed]
PHST- 2020/02/15 06:00 [medline]
PHST- 2018/01/27 06:00 [entrez]
AID - S0003-9861(17)30840-8 [pii]
AID - 10.1016/j.abb.2018.01.013 [doi]
PST - ppublish
SO  - Arch Biochem Biophys. 2019 Apr 15;665:69-78. doi: 10.1016/j.abb.2018.01.013. Epub 
      2018 Jan 31.